DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,702,384 | -2.1% | 10,892 | -5.3% | 0.48% | +3.2% |
| Q2 2023 | $2,760,548 | -8.4% | 11,502 | -3.8% | 0.47% | -14.6% |
| Q1 2023 | $3,014,459 | -8.5% | 11,960 | -3.6% | 0.55% | -13.6% |
| Q4 2022 | $3,293,386 | +1.9% | 12,408 | -0.8% | 0.63% | -8.9% |
| Q3 2022 | $3,231,000 | -8.9% | 12,508 | -10.6% | 0.70% | +6.4% |
| Q2 2022 | $3,547,000 | -15.8% | 13,991 | -2.6% | 0.65% | -2.8% |
| Q1 2022 | $4,212,000 | -12.2% | 14,361 | -1.6% | 0.67% | -9.5% |
| Q4 2021 | $4,800,000 | +6.4% | 14,588 | -1.5% | 0.74% | -3.8% |
| Q3 2021 | $4,510,000 | +11.0% | 14,814 | -2.2% | 0.77% | +8.7% |
| Q2 2021 | $4,064,000 | +18.4% | 15,142 | -0.7% | 0.71% | +10.4% |
| Q1 2021 | $3,433,000 | -0.9% | 15,254 | -2.1% | 0.64% | -14.0% |
| Q4 2020 | $3,463,000 | +2.7% | 15,589 | -0.5% | 0.75% | -14.9% |
| Q3 2020 | $3,373,000 | +17.8% | 15,664 | -3.2% | 0.88% | +1.3% |
| Q2 2020 | $2,863,000 | +27.2% | 16,190 | -0.4% | 0.87% | -3.3% |
| Q1 2020 | $2,250,000 | -11.5% | 16,255 | -1.9% | 0.90% | +4.5% |
| Q4 2019 | $2,543,000 | +4.6% | 16,572 | -1.6% | 0.86% | -6.4% |
| Q3 2019 | $2,432,000 | +1.5% | 16,838 | +0.4% | 0.92% | -1.7% |
| Q2 2019 | $2,396,000 | +5.0% | 16,765 | -3.0% | 0.94% | -2.1% |
| Q1 2019 | $2,281,000 | +27.5% | 17,275 | -0.4% | 0.96% | +20.1% |
| Q4 2018 | $1,789,000 | -7.7% | 17,352 | -2.8% | 0.80% | +11.2% |
| Q3 2018 | $1,939,000 | +12.3% | 17,847 | +2.0% | 0.72% | +6.4% |
| Q2 2018 | $1,727,000 | +0.5% | 17,505 | -0.2% | 0.67% | -7.2% |
| Q1 2018 | $1,718,000 | +1.8% | 17,545 | -3.5% | 0.72% | +3.1% |
| Q4 2017 | $1,688,000 | +6.4% | 18,184 | -1.7% | 0.70% | -2.1% |
| Q3 2017 | $1,586,000 | +2.8% | 18,491 | +1.1% | 0.72% | -0.1% |
| Q2 2017 | $1,543,000 | -0.4% | 18,283 | +0.9% | 0.72% | -4.5% |
| Q1 2017 | $1,549,000 | +12.2% | 18,113 | +2.1% | 0.75% | +7.6% |
| Q4 2016 | $1,381,000 | +11.6% | 17,748 | +12.5% | 0.70% | +2.2% |
| Q3 2016 | $1,237,000 | -22.4% | 15,778 | 0.0% | 0.68% | -25.2% |
| Q2 2016 | $1,594,000 | +7.7% | 15,778 | +1.1% | 0.92% | +3.5% |
| Q1 2016 | $1,480,000 | -3.1% | 15,602 | -5.2% | 0.88% | -8.7% |
| Q4 2015 | $1,528,000 | +6.0% | 16,451 | -2.8% | 0.97% | -2.2% |
| Q3 2015 | $1,442,000 | +2.1% | 16,925 | +2.5% | 0.99% | +10.2% |
| Q2 2015 | $1,413,000 | +3.4% | 16,505 | +2.6% | 0.90% | +6.1% |
| Q1 2015 | $1,366,000 | – | 16,084 | – | 0.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |